 - Patients must have high risk non-muscle invasive urothelial bladder carcinoma Tis, TaHG, or T1 that is pathologically confirmed by the Memorial Sloan Kettering Department of Pathology or a documented history of TaHG or T1 non-muscle invasive urothelial bladder tumors. 